|
|
Article: Aventis Submits New Drug Application With U.S. Food and Drug Administration For Once Daily Formulation of Allegra-D(R) (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg).
- Article from:
- PR Newswire
- Article date:
- December 29, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Aventis announced today the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Allegra-D 24 hour tablets (fexofenadine HCl 180 mg/pseudophedrine HCl 240 mg). The company is seeking marketing approval for a once daily formulation for the treatment of seasonal allergy symptoms with nasal congestion in adults and children 12 years of age and older. Aventis currently markets twice daily Allegra-D (fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg) extended release tablets.
As many as 40 million adults and children in the United States suffer from seasonal allergies and associated symptoms, such as nasal congestion, watery ...